Business
Vor Biopharma Adds R&D Leader Bill Lundberg to BOD
Vor Biopharma Adds R&D Leader Bill Lundberg to BOD.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \nRNS Number : 4124H PureTech Health PLC 31 July 2019 \n\n31 July 2019\n \nPureTech Health plc\n \nPureTech Affiliate Vor Biopharma Appoints Bill Lundberg, MD, to Board of Directors\n \nPureTech Health plc (LSE: PRTC) (\"PureTech\"), an advanced biopharmaceutical company developing novel medicines for dysfunctions of the Brain-Immune-Gut (BIG) axis, today announced that its affiliate Vor Biopharma has appointed Bill Lundberg, MD, to its Board of Directors.\n \nDr Lundberg is a medical oncologist with deep experience running drug discovery and development. He was the first employee and founding chief scientific officer at CRISPR Therapeutics and led development of the company's first clinical trial application. He has also held leadership roles at Taligen Therapeutics and Alexion Pharmaceuticals.\n \nThe full release from Vor Biopharma is as follows:\n \nVor Biopharma Appoints Dr Bill Lundberg to its Board of Directors\n \nVor expands expert governance and oversight with highly regarded physician-scientist and R&D leader\n \nCAMBRIDGE, July 31, 2019 - Vor Biopharma, an oncology company pioneering engineered haematopoietic stem cells (eHSCs) for the treatment of haematological cancers, today announced the appointment of Bill Lundberg, MD, to its Board of Directors.\n \nDr Lundberg is a medical oncologist with more than 15 years of experience managing and leading biotechnology research and development. Most recently, Dr Lundberg served as Chief Scientific Officer at CRISPR Therapeutics, establishing the company in Cambridge, Mass. as the first US employee and leading the development of the company's first clinical trial application. Dr Lundberg was previously Director and Chief Medical Officer of Taligen Therapeutics and Vice President and Head of Translational Medicine at Alexion Pharmaceuticals, where he oversaw R&D from discovery through early clinical development. Prior to this, Dr Lundberg held roles of increasing responsibility in drug development and medical affairs at Xanthus (acquired by Antisoma), Wyeth (now Pfizer) and Genzyme.\n \n\"Patients with haematologic malignancies, particularly myeloid malignancies, need new, potentially curative treatments. Vor's completely different approach to unlocking the potential of cancer immunotherapy for acute myeloid l...